Which has stronger valuation and earnings, NXTC or KYNB?

Kyntra Bio has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A Kyntra Bio $6.44M 4.45 $183.45M $40.46 0.17

Is NXTC or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to NextCure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Kyntra Bio 2,199.13% N/A -36.71%

Do analysts recommend NXTC or AIXC?

NextCure currently has a consensus target price of $23.00, indicating a potential upside of 1,328.57%. Given NextCure's stronger consensus rating and higher probable upside, equities research analysts clearly believe NextCure is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NXTC or AIXC?

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is NXTC or AIXC more profitable?

NextCure's return on equity of -186.96% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Qualigen Therapeutics N/A -771.52% -79.52%

Do analysts prefer LITS or NXTC?

NextCure has a consensus price target of $23.00, suggesting a potential upside of 1,328.57%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is LITS or NXTC more profitable?

Lite Strategy's return on equity of -90.81% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Lite Strategy N/A -90.81% -89.33% NextCure N/A -186.96% -124.62%

Do analysts recommend TXMD or NXTC?

NextCure has a consensus target price of $23.00, indicating a potential upside of 1,328.57%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is TXMD or NXTC more profitable?

TherapeuticsMD has a net margin of 5.34% compared to NextCure's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets TherapeuticsMD 5.34% 0.32% 0.23% NextCure N/A -186.96% -124.62%

Which has better earnings and valuation, SKYE or NXTC?

Skye Bioscience is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A NextCure N/A N/A -$55.84M -$17.19 N/A

Is SKYE or NXTC more profitable?

NextCure's return on equity of -186.96% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% NextCure N/A -186.96% -124.62%

NextCure (NXTC) Competitors

$1.61 -0.16 (-9.04%)

As of 02:18 PM Eastern

Compare

NXTC vs. KYNB, AIXC, LITS, TXMD, and SKYE

Should you buy NextCure stock or one of its competitors? MarketBeat compares NextCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NextCure include Kyntra Bio (KYNB), Qualigen Therapeutics (AIXC), Lite Strategy (LITS), TherapeuticsMD (TXMD), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does NextCure compare to Kyntra Bio?

NextCure (NASDAQ:NXTC) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Kyntra Bio has a net margin of 2,199.13% compared to NextCure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Kyntra Bio	2,199.13%	N/A	-36.71%

NextCure presently has a consensus target price of $23.00, suggesting a potential upside of 1,328.57%. Kyntra Bio has a consensus target price of $30.00, suggesting a potential upside of 324.03%. Given NextCure's higher probable upside, equities analysts clearly believe NextCure is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

42.7% of NextCure shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 11.9% of NextCure shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NextCure has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Kyntra Bio has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Kyntra Bio	$6.44M	4.45	$183.45M	$40.46	0.17

In the previous week, NextCure's average media sentiment score of 0.00 equaled Kyntra Bio'saverage media sentiment score.

Company	Overall Sentiment
NextCure	Neutral
Kyntra Bio	Neutral

Summary

Kyntra Bio beats NextCure on 10 of the 14 factors compared between the two stocks.

How does NextCure compare to Qualigen Therapeutics?

NextCure (NASDAQ:NXTC) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

NextCure currently has a consensus target price of $23.00, indicating a potential upside of 1,328.57%. Given NextCure's stronger consensus rating and higher probable upside, equities research analysts clearly believe NextCure is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NextCure's return on equity of -186.96% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

NextCure has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

In the previous week, Qualigen Therapeutics had 2 more articles in the media than NextCure. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for NextCure. NextCure's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
NextCure	Neutral
Qualigen Therapeutics	Neutral

42.7% of NextCure shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

NextCure beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.

How does NextCure compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and NextCure (NASDAQ:NXTC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Lite Strategy has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, NextCure has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 1.6% of Lite Strategy shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lite Strategy's return on equity of -90.81% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-90.81%	-89.33%
NextCure	N/A	-186.96%	-124.62%

Lite Strategy has higher revenue and earnings than NextCure. Lite Strategy is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lite Strategy	$65.30M	0.42	-$15.94M	-$1.60	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

In the previous week, Lite Strategy had 4 more articles in the media than NextCure. MarketBeat recorded 4 mentions for Lite Strategy and 0 mentions for NextCure. Lite Strategy's average media sentiment score of 0.57 beat NextCure's score of 0.00 indicating that Lite Strategy is being referred to more favorably in the media.

Company	Overall Sentiment
Lite Strategy	Positive
NextCure	Neutral

NextCure has a consensus price target of $23.00, suggesting a potential upside of 1,328.57%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Lite Strategy beats NextCure on 8 of the 14 factors compared between the two stocks.

How does NextCure compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

NextCure has a consensus target price of $23.00, indicating a potential upside of 1,328.57%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

TherapeuticsMD has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, NextCure has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to NextCure's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
NextCure	N/A	-186.96%	-124.62%

In the previous week, TherapeuticsMD's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
NextCure	Neutral

TherapeuticsMD has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.12	-$570K	$0.06	35.33
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 11.9% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

TherapeuticsMD beats NextCure on 7 of the 13 factors compared between the two stocks.

How does NextCure compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

NextCure's return on equity of -186.96% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
NextCure	N/A	-186.96%	-124.62%

In the previous week, Skye Bioscience's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
Skye Bioscience	Neutral
NextCure	Neutral

Skye Bioscience is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

Skye Bioscience has a beta of 2.95, suggesting that its share price is 195% more volatile than the broader market. Comparatively, NextCure has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Skye Bioscience currently has a consensus target price of $8.50, suggesting a potential upside of 1,114.29%. NextCure has a consensus target price of $23.00, suggesting a potential upside of 1,328.57%. Given NextCure's higher probable upside, analysts plainly believe NextCure is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

NextCure beats Skye Bioscience on 8 of the 12 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXTC vs. The Competition

Export

Metric	NextCure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.81M	$3.55B	$6.66B	$12.19B
Dividend Yield	N/A	2.28%	2.68%	5.89%
P/E Ratio	-0.09	21.26	25.35	24.07
Price / Sales	N/A	329.81	588.85	125.28
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	0.16	8.14	10.56	6.37
Net Income	-$55.84M	$23.91M	$3.56B	$337.11M
7 Day Performance	-20.30%	1.80%	1.00%	-0.93%
1 Month Performance	-79.44%	2.10%	0.80%	0.65%
1 Year Performance	-71.22%	57.20%	31.01%	29.50%

NextCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXTC NextCure	2.3239 of 5 stars	$1.61 -9.0%	$23.00 +1,328.6%	-68.3%	$5.81M	N/A	N/A	90	Positive News
KYNB Kyntra Bio	2.7144 of 5 stars	$6.91 +0.6%	$30.00 +334.2%	N/A	$27.81M	$6.44M	N/A	570	News Coverage Gap Up
AIXC Qualigen Therapeutics	0.1494 of 5 stars	$1.49 +8.8%	N/A	N/A	$27.72M	N/A	N/A	50	High Trading Volume
LITS Lite Strategy	0.9854 of 5 stars	$0.92 +14.9%	N/A	N/A	$27.24M	$65.30M	N/A	100	High Trading Volume
TXMD TherapeuticsMD	0.7946 of 5 stars	$2.29 +0.4%	N/A	+70.3%	$26.39M	$3.02M	N/A	420	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXTC) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NextCure (NXTC) Competitors

NXTC vs. KYNB, AIXC, LITS, TXMD, and SKYE

How does NextCure compare to Kyntra Bio?

Summary

How does NextCure compare to Qualigen Therapeutics?

Summary

How does NextCure compare to Lite Strategy?

Summary

How does NextCure compare to TherapeuticsMD?

Summary

How does NextCure compare to Skye Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NextCure (NXTC) Competitors

NXTC vs. KYNB, AIXC, LITS, TXMD, and SKYE

How does NextCure compare to Kyntra Bio?

Is NXTC or KYNB more profitable?

Do analysts recommend NXTC or KYNB?

Do institutionals & insiders believe in NXTC or KYNB?

Which has more risk & volatility, NXTC or KYNB?

Which has stronger valuation and earnings, NXTC or KYNB?

Does the media refer more to NXTC or KYNB?

Summary

How does NextCure compare to Qualigen Therapeutics?

Do analysts recommend NXTC or AIXC?

Is NXTC or AIXC more profitable?

Which has more risk and volatility, NXTC or AIXC?

Which has better valuation and earnings, NXTC or AIXC?

Does the media prefer NXTC or AIXC?

Do institutionals and insiders have more ownership in NXTC or AIXC?

Summary

How does NextCure compare to Lite Strategy?

Which has more volatility & risk, LITS or NXTC?

Do institutionals and insiders hold more shares of LITS or NXTC?

Is LITS or NXTC more profitable?

Which has preferable valuation & earnings, LITS or NXTC?

Does the media favor LITS or NXTC?

Do analysts prefer LITS or NXTC?

Summary

How does NextCure compare to TherapeuticsMD?

Do analysts recommend TXMD or NXTC?

Which has more volatility & risk, TXMD or NXTC?

Is TXMD or NXTC more profitable?

Does the media refer more to TXMD or NXTC?

Which has higher valuation and earnings, TXMD or NXTC?

Do institutionals & insiders have more ownership in TXMD or NXTC?

Summary

How does NextCure compare to Skye Bioscience?

Is SKYE or NXTC more profitable?

Does the media favor SKYE or NXTC?

Which has better earnings and valuation, SKYE or NXTC?

Which has more risk and volatility, SKYE or NXTC?

Do institutionals & insiders believe in SKYE or NXTC?

Do analysts rate SKYE or NXTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC vs. The Competition

NextCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools